Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic heparin after repair of penetrating upper limb arterial trauma
IRCT20190717044255N3Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Dec 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of heparin in arterial injury and Upper extremity vascular injury (UEVI) (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoint: Upper extremity blood supply. Started Dec 2021; status: completed.
02
Drugs
heparin
03
Conditions
arterial injuryUpper extremity vascular injury (UEVI)
Beyond the preview
Go deeper on IRCT20190717044255N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190717044255N3.